Navigation Links
Two New Jersey Hormone Therapy Lawsuits Dismissed
Date:7/14/2008

MADISON, N.J., July 14 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that Judge Jamie D. Happas of the New Jersey Superior Court in New Brunswick has granted Wyeth's motion for summary judgment in two hormone therapy cases that were scheduled for trial later this year. The court dismissed the cases of Bailey v. Wyeth, which was to have begun on September 15, and DeBoard v. Wyeth, which had an October 27 trial date. The plaintiffs in both cases alleged they developed breast cancer as a result of the use of Prempro(TM) and Premarin(R), hormone therapy products marketed by Wyeth, as well as Provera(R), a progestin product marketed by Upjohn.

In granting the motions, Judge Happas ruled, among other things, that the plaintiffs "failed to provide the specific type of evidence necessary to overcome the presumption of adequacy afforded [to] FDA-approved labeling" by New Jersey law and that the warnings were "adequate as a matter of law."

"We believe the court's ruling was a proper application of New Jersey law and is consistent with a growing body of law around the nation, rejecting challenges to FDA-approved labeling," says Lauren E. Handler, a partner with Porzio Bromberg & Newman, P.C., a New Jersey-based firm representing Wyeth in both cases.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. World Chemical Industry Has Decided to Gather at ChemOutsourcing Show on September 7-9 in New Jersey
2. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
3. E. coli Outbreak in New Jersey?
4. API and Raw Material Supply Concerns Focal Point of Pharma ChemOutsourcing Conference September 8-9 in New Jersey
5. Chemistry Outsourcing Conference Unveils 90-Speaker Conference Program to Take Place September 8-9 in New Jersey
6. StemCyte Locates East Coast Operations in New Jersey
7. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
8. Novo Nordisk Expands U.S. Headquarters in New Jersey
9. BioSpace New Jersey Career Fair Attracts Over 1,000 Bioscience Candidates
10. NicOx Opens U.S. Headquarters in New Jersey
11. Secure Symbology: Making New Jersey Proud While Saving Lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):